Chronic Low-back Pain
Conditions
Brief summary
The purpose of this study is to test whether LY3526318 is efficacious and safe in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Interventions
DRUGLY3526318
Administered orally
DRUGPlacebo
Administered orally
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have a visual analog scale (VAS) pain value ≥40 and \<95 during screening. * Have a history of daily pain for at least 12 weeks based on participant report or medical history. * Have a body mass index \<40 kilograms per meter squared (kg/m²) (inclusive). * Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation. * Are willing to discontinue all medications taken for chronic pain conditions for the duration of the study. * Are at 18 years old or older at the time consent is signed. * Have a history of low back pain for at least 3 months located between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation. * Have a history of low back pain as classified by the Quebec Task Force Category 1 through 3. * Are men, or women able to abide by reproductive and contraceptive requirements.
Exclusion criteria
* Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques). * Have surgery planned during the study for any reason, related or not to the disease state under evaluation. * Have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation. * Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision. * Have fibromyalgia * Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association). * Have a positive human immunodeficiency virus (HIV) test result at screening. * Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide. * Have an intolerance to acetaminophen or paracetamol or any of its excipients. * Have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening. * Have used a therapeutic injection (botulinum toxin or corticosteroids) in the 3 months prior to starting the washout period. * Have history of or current compression fracture. * Have had a recent major trauma (within 6 months of baseline). * Have a history of low back pain as classified by the Quebec Task Force categories 4 through 11. * Are using a spinal cord stimulator or dorsal root ganglion stimulator. * Are pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) at Week 4 | Baseline, Week 4 | The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline on the Roland Morris Disability Questionnaire (RMDQ) | Baseline, Week 4 | The RMDQ is a simple, sensitive, and reliable method to measure disability in patients with back pain that consists of 24 statements relating to the person's perceptions of back pain and associated disability based on physical ability/activity, sleep/rest, psychosocial, household management, eating, and pain frequency. Participants are asked if they feel the statement is descriptive of their own circumstance on that day. The total score is obtained by counting the number of ''Yes'' responses, ranging from: 0 = no disability to 24 = maximal disability. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval. |
| Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change | Baseline, Week 4 | Patients Global Impression of Change captured the participant's perspective of treatment apart from sub-aspects of the general improvement. This is a numeric scale from 1 to 7 where, 1=very much better, and 7=very much worse. Posterior mean, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval. |
| Change From Baseline for Worst Pain Intensity as Measured by NRS | Baseline, Week 4 | The NRS was used to describe pain severity. Participants were asked to describe their worst pain over the past 24 hours, on a scale of 0 to 10: 0=no pain, and 10=pain as bad as you can imagine. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval. |
| Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) | Baseline, Week 8 | The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval. |
| Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep | Baseline, Week 4 | The MOS Sleep Scale consists of 12 questions addressing the past week. Question 1 asks time to fall asleep and it is reported in 5-point timeframe categories. Question 2 asks average hours of sleep. In the remaining 10 questions participants report how often a sleep symptom or problem was present on a scale ranging from '0=all of the time' to '5=none of the time.' MOS Sleep scale dimension scores range from 0 to 100 with lower score indicating improvement, except for the dimension of sleep adequacy, where higher scores indicate improvement. Here, the average hours of sleep (i.e., Question 2) is reported as the average number of hours slept each night during the past week (range 0 to 24 hours). Higher number of hours slept indicates improvement. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval. |
| Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm) | Baseline, Week 4 | The EQ-5D-5L assessed quality of life based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant was asked to 'check the ONE box that best describes your health TODAY,' choosing from 5 options (no problems, slight problems, moderate problems, severe problems, extreme problems) provided under each dimension. The scores in the 5 dimensions were summarized into a health state index score using the United States algorithm. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health: 0=a health state equivalent to death, and 1=perfect health. Posterior mean change from baseline, 95% credible intervals was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval. |
| Total Amount of Rescue Medication Use as Measured by Average Daily Dosage | Week 4 | Total amount of rescue medication use as measured by average daily dosage. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval. |
| Change From Baseline on the Visual Analog Scale (VAS) for Pain | Baseline, Week 4 | VAS was a graphic, single-item scale where participants were asked to describe their pain intensity over the past week, on a scale of 0 to 100: 0=no pain, and 100=worst imaginable pain. Participants completed the VAS by placing a line perpendicular to the VAS line at a point that described their pain intensity. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval. |
Countries
Puerto Rico, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 250 mg LY3526318 Participants received 250 mg of LY3526318 orally, once daily for the first 4 weeks of treatment period and were switched to placebo once daily for the next 4 weeks of the treatment period. | 105 |
| Placebo Participants received placebo orally, once daily, for 8-weeks treatment period. | 54 |
| Total | 159 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 4 | 2 |
| Overall Study | Lost to Follow-up | 2 | 0 |
| Overall Study | Non-compliance with study drug | 2 | 1 |
| Overall Study | Physician Decision | 2 | 0 |
| Overall Study | Withdrawal by Subject | 5 | 2 |
Baseline characteristics
| Characteristic | 250 mg LY3526318 | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 54.00 years STANDARD_DEVIATION 13.2 | 54.30 years STANDARD_DEVIATION 13.74 | 54.10 years STANDARD_DEVIATION 13.34 |
| Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) | 5.56 score on a scale STANDARD_DEVIATION 1.57 | 5.79 score on a scale STANDARD_DEVIATION 1.54 | 5.64 score on a scale STANDARD_DEVIATION 1.56 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 25 Participants | 15 Participants | 40 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 80 Participants | 39 Participants | 119 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 3 Participants | 6 Participants | 9 Participants |
| Race (NIH/OMB) Black or African American | 14 Participants | 6 Participants | 20 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) White | 84 Participants | 42 Participants | 126 Participants |
| Region of Enrollment Puerto Rico | 2 Participants | 2 Participants | 4 Participants |
| Region of Enrollment United States | 103 Participants | 52 Participants | 155 Participants |
| Sex: Female, Male Female | 66 Participants | 35 Participants | 101 Participants |
| Sex: Female, Male Male | 39 Participants | 19 Participants | 58 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 105 | 0 / 92 | 0 / 54 | 0 / 50 |
| other Total, other adverse events | 36 / 105 | 14 / 92 | 19 / 54 | 5 / 50 |
| serious Total, serious adverse events | 2 / 105 | 0 / 92 | 0 / 54 | 0 / 50 |
Outcome results
Primary
Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) at Week 4
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 4
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 4.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) at Week 4 | -1.28 score on a scale |
| Placebo | Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) at Week 4 | -0.90 score on a scale |
95% CI: [-0.89, 0.13]
Secondary
Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 8
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 8.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) | -1.47 score on a scale |
| Placebo | Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) | -1.20 score on a scale |
95% CI: [-0.85, 0.3]
Secondary
Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change
Patients Global Impression of Change captured the participant's perspective of treatment apart from sub-aspects of the general improvement. This is a numeric scale from 1 to 7: 1 = very much better, and 7 = very much worse. Posterior mean, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 8
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 8.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change | 3.00 score on a scale |
| Placebo | Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change | 3.26 score on a scale |
95% CI: [-0.67, 0.14]
Secondary
Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change
Patients Global Impression of Change captured the participant's perspective of treatment apart from sub-aspects of the general improvement. This is a numeric scale from 1 to 7 where, 1=very much better, and 7=very much worse. Posterior mean, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 4
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 4.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change | 3.13 score on a scale |
| Placebo | Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change | 3.25 score on a scale |
95% CI: [-0.44, 0.19]
Secondary
Change From Baseline for Worst Pain Intensity as Measured by NRS
The NRS was used to describe pain severity. Participants were asked to describe their worst pain over the past 24 hours, on a scale of 0 to 10: 0=no pain, and 10=pain as bad as you can imagine. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 4
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 4.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline for Worst Pain Intensity as Measured by NRS | -1.45 score on a scale |
| Placebo | Change From Baseline for Worst Pain Intensity as Measured by NRS | -0.97 score on a scale |
95% CI: [-1.05, 0.09]
Secondary
Change From Baseline for Worst Pain Intensity as Measured by NRS
The NRS was used to describe pain severity. Participants were asked to describe their worst pain over the past 24 hours, on a scale of 0 to 10: 0=no pain, and 10=pain as bad as you can imagine. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 8
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 8.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline for Worst Pain Intensity as Measured by NRS | -1.69 score on a scale |
| Placebo | Change From Baseline for Worst Pain Intensity as Measured by NRS | -1.18 score on a scale |
95% CI: [-1.17, 0.16]
Secondary
Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm)
The EQ-5D-5L assessed quality of life based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant was asked to 'check the ONE box that best describes your health TODAY,' choosing from 5 options (no problems, slight problems, moderate problems, severe problems, extreme problems) provided under each dimension. The scores in the 5 dimensions were summarized into a health state index score using the United States algorithm. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health: 0=a health state equivalent to death, and 1=perfect health. Posterior mean change from baseline, 95% credible intervals was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 8
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 8.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm) | 0.05 score on a scale |
| Placebo | Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm) | 0.03 score on a scale |
95% CI: [-0.05, 0.1]
Secondary
Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm)
The EQ-5D-5L assessed quality of life based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant was asked to 'check the ONE box that best describes your health TODAY,' choosing from 5 options (no problems, slight problems, moderate problems, severe problems, extreme problems) provided under each dimension. The scores in the 5 dimensions were summarized into a health state index score using the United States algorithm. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health: 0=a health state equivalent to death, and 1=perfect health. Posterior mean change from baseline, 95% credible intervals was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 4
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 4.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm) | 0.02 score on a scale |
| Placebo | Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm) | 0.01 score on a scale |
95% CI: [-0.06, 0.07]
Secondary
Change From Baseline on the Roland Morris Disability Questionnaire (RMDQ)
The RMDQ is a simple, sensitive, and reliable method to measure disability in patients with back pain that consists of 24 statements relating to the person's perceptions of back pain and associated disability based on physical ability/activity, sleep/rest, psychosocial, household management, eating, and pain frequency. Participants are asked if they feel the statement is descriptive of their own circumstance on that day. The total score is obtained by counting the number of ''Yes'' responses, ranging from: 0 = no disability to 24 = maximal disability. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 4
Population: All enrolled who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 4.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline on the Roland Morris Disability Questionnaire (RMDQ) | -2.03 score on a scale |
| Placebo | Change From Baseline on the Roland Morris Disability Questionnaire (RMDQ) | -1.42 score on a scale |
95% CI: [-1.91, 0.68]
Secondary
Change From Baseline on the Roland Morris Disability Questionnaire (RMDQ)
The RMDQ is a simple, sensitive, and reliable method to measure disability in patients with back pain that consists of 24 statements relating to the person's perceptions of back pain and associated disability based on physical ability/activity, sleep/rest, psychosocial, household management, eating, and pain frequency. Participants are asked if they feel the statement is descriptive of their own circumstance on that day. The total score is obtained by counting the number of ''Yes'' responses, ranging from: 0 = no disability to 24 = maximal disability. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 8
Population: All enrolled who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 8.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline on the Roland Morris Disability Questionnaire (RMDQ) | -2.55 score on a scale |
| Placebo | Change From Baseline on the Roland Morris Disability Questionnaire (RMDQ) | -1.37 score on a scale |
95% CI: [-2.54, 0.18]
Secondary
Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep
The MOS Sleep Scale consists of 12 questions addressing the past week. Question 1 asks time to fall asleep and it is reported in 5-point timeframe categories. Question 2 asks average hours of sleep. In the remaining 10 questions participants report how often a sleep symptom or problem was present on a scale ranging from '0=all of the time' to '5=none of the time.' MOS Sleep scale dimension scores range from 0 to 100 with lower score indicating improvement, except for the dimension of sleep adequacy, where higher scores indicate improvement. Here, the average hours of sleep (i.e., Question 2) is reported as the average number of hours slept each night during the past week (range 0 to 24 hours). Higher number of hours slept indicates improvement. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 4
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 4.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep | 0.11 Hours per night |
| Placebo | Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep | 0.24 Hours per night |
95% CI: [-0.46, 0.21]
Secondary
Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep
The MOS Sleep Scale consists of 12 questions addressing the past week. Question 1 asks time to fall asleep and it is reported in 5-point timeframe categories. Question 2 asks average hours of sleep. In the remaining 10 questions participants report how often a sleep symptom or problem was present on a scale ranging from '0=all of the time' to '5=none of the time.' MOS Sleep scale dimension scores range from 0 to 100 with lower score indicating improvement, except for the dimension of sleep adequacy, where higher scores indicate improvement. Here, the average hours of sleep (i.e., Question 2) is reported as the average number of hours slept each night during the past week (range 0 to 24 hours). Higher number of hours slept indicates improvement. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 8
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 8.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep | 5.04 Hours per night |
| Placebo | Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep | 3.52 Hours per night |
95% CI: [-6.2, 9.2]
Secondary
Change From Baseline on the Visual Analog Scale (VAS) for Pain
VAS was a graphic, single-item scale where participants were asked to describe their pain intensity over the past week, on a scale of 0 to 100: 0=no pain, and 100=worst imaginable pain. Participants completed the VAS by placing a line perpendicular to the VAS line at a point that described their pain intensity. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 4
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 4.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline on the Visual Analog Scale (VAS) for Pain | -14.84 score on a scale |
| Placebo | Change From Baseline on the Visual Analog Scale (VAS) for Pain | -9.89 score on a scale |
95% CI: [-11.07, 1.27]
Secondary
Change From Baseline on the Visual Analog Scale (VAS) for Pain
VAS was a graphic, single-item scale where participants were asked to describe their pain intensity over the past week, on a scale of 0 to 100: 0=no pain, and 100=worst imaginable pain. Participants completed the VAS by placing a line perpendicular to the VAS line at a point that described their pain intensity. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Baseline, Week 8
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 8.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Change From Baseline on the Visual Analog Scale (VAS) for Pain | -19.50 score on a scale |
| Placebo | Change From Baseline on the Visual Analog Scale (VAS) for Pain | -14.72 score on a scale |
95% CI: [-11.73, 2.15]
Secondary
Total Amount of Rescue Medication Use as Measured by Average Daily Dosage
Total amount of rescue medication use as measured by average daily dosage. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Week 8
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 8.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Total Amount of Rescue Medication Use as Measured by Average Daily Dosage | 237.79 mg per day (mg/day) |
| Placebo | Total Amount of Rescue Medication Use as Measured by Average Daily Dosage | 228.06 mg per day (mg/day) |
95% CI: [-151.11, 170.52]
Secondary
Total Amount of Rescue Medication Use as Measured by Average Daily Dosage
Total amount of rescue medication use as measured by average daily dosage. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Time frame: Week 4
Population: All enrolled participants who received at least one dose of study drug. Here, the overall number of participants analyzed includes the number of participants with non-missing value at Week 4.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 250 mg LY3526318 | Total Amount of Rescue Medication Use as Measured by Average Daily Dosage | 229.99 mg per day (mg/day) |
| Placebo | Total Amount of Rescue Medication Use as Measured by Average Daily Dosage | 188.27 mg per day (mg/day) |
95% CI: [-95.92, 179.76]